2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting in Chicago, IL from June 1-5, 2018 via the following four presentation categories:

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• DCTD Staff Kiosk Schedule

Oral Presentations

Time	Title	Location
Friday, June 1
3:45 PM — 3:57 PM	Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway	S406
Saturday, June 2
8:00 AM — 8:12 AM	Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial	Hall D1
8:12 AM — 8:24 AM	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors	Hall D1
4:00 PM — 4:12 PM	SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, Arry-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)	S504
Sunday, June 3
12:10 PM — 12:30 PM	Rational Approach to Utilizing Genetic Information Elise Kohn, MD, Cancer Therapy Evaluation Program	S100bc
1:45 PM — 2:00 PM	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score	Hall B1
Monday, June 4
8:00 AM — 8:12 AM	Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105)	S100a
10:00 AM — 10:12 AM	Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy	Arie Crown Theater
5:05 PM — 5:25 PM	Next-Generation Platform Trials: Innovation in trial design Optimal source for molecular characterization Mickey Williams, PhD, Frederick National Laboratory for Cancer Research	S100a
Tuesday, June 5
8:00 AM — 8:20 AM	Coming Soon? New Treatments in Ovarian Cancer Charles Kunos, MD, PhD, Cancer Therapy Evaluation Program	S100a

Poster Presentations

Time	Title	Location
Saturday, June 2
8:00 AM — 11:30 AM	A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB)	Hall A Abstract 10522 Poster #195
8:00 AM — 11:30 AM	Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors	Hall A Abstract 10551 Poster #224
1:15 PM — 4:45 PM	Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer	Hall A Abstract 6087 Poster #75
1:15 PM — 4:45 PM	Use of next-generation sequencing test to guide cancer treatment: Results from a survey of U.S. oncologists	Hall A Abstract 6529 Poster #355
1:15 PM — 4:45 PM	Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204	Hall A Abstract 6600 Poster #425
Sunday, June 3
8:00 AM — 11:30 AM	NCI 10066: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma	Hall A Abstract TPS4137 Poster #323a
8:00 AM — 11:30 AM	Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228	Hall A Abstract 9098 Poster #421
Monday, June 4
8:00 AM — 11:30 AM	Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers Geraldine O’Sullivan Coyne, MD, PhD, Developmental Therapeutics Clinic	Hall A Abstract TPS3128 Poster #328b
8:00 AM — 11:30 AM	Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor-positive solid tumors including desmoid and gynecologic tumors Naoko Takebe, MD, PhD, Developmental Therapeutics Clinic	Hall A Abstract 2516 Poster #342
8:00 AM — 11:30 AM	Adverse events (AEs) in early phase cancer clinical trials Grace Mishkin, MPH, Cancer Therapy Evaluation Program	Hall A Abstract 2542 Poster #368
8:00 AM — 11:30 AM	FACTS: Factors affecting combination trial success	Hall A Abstract 2544 Poster #370
8:00 AM — 11:30 AM	Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors Geraldine O’Sullivan Coyne, MD, PhD, Developmental Therapeutics Clinic	Hall A Abstract 2549 Poster #375
8:00 AM — 11:30 AM	BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of MCl-1 inhibitors to evaluate in vivo effectiveness Apurva Srivastava, PhD, Frederick National Laboratory for Cancer Research	Hall A Abstract 2582 Poster #408
8:00 AM — 11:30 AM	Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD 1775 Naoko Takebe, MD, PhD, Developmental Therapeutics Clinic	Hall A Abstract 2587 Poster #413
8:00 AM — 11:30 AM	AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL)	Hall A Abstract TPS2597 Poster #422b
8:00 AM — 11:30 AM	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer	Hall A Abstract TPS2608 Poster #428a
1:15 PM — 4:45 PM	Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBG): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials	Hall A Abstract 10065 Poster #53
1:15 PM — 4:45 PM	Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial	Hall A Abstract 10067 Poster #55
1:15 PM — 4:45 PM	Assessment of the genomic stability and molecular landscape of patient-derived xenograft (PDX) models from NCI’s Patient-Derived Models Repository Biswajit Das, PhD, Frederick National Laboratory for Cancer Research	Hall A Abstract 12023 Poster #136
1:15 PM — 4:45 PM	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca)	Hall A Abstract 5519 Poster #246
1:15 PM — 4:45 PM	Toxicity profile of patients with gynecological cancers (Gyne) enrolled phase I trials	Hall A Abstract 5572 Poster #299
1:15 PM — 4:45 PM	Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes	Hall A Abstract 9569 Poster #396

Meet-the-Expert Presentations

NCI Exhibit Booth # 5041

DCTD Staff Kiosk Schedule

NCI Exhibit Booth # 5041